Effectiveness of Antiviral Therapy in Hepatitis B Virus-related Hepatocellular Carcinoma Initially Treated with Transarterial Chemoembolization: a Multicenter Retro spective Study = Effectiveness of Antiviral Therapy in Hepatitis B Virus-related Hepatocellular Carcinoma Initially Treated with Transarterial Chemoembolization: a Multicenter Retro spective Study

다국어 초록 (Multilingual Abstract)

Aims: It remains uncertain whether antiviral treatment improve surivival in hepatitis B virus (HBV)-hepatocellular carcinoma (HCC) patients receiving palliative therapy. The purpose of this study is to evaluate the role of antiviral therapy in HBV-HCC patients after diagnosis of HCC.
Methods: This retrospective study analyzed 113 HBV-HCC patients who underwent transarterial chemoembolization (TACE) in two university hospital. Overall survival (OS) was compared in patients treated with/without antiviral treatment after diagnosis of HCC. Subgroup analysis and Cox regression analysis were performed to determine the efficiency of antiviral treatment and prognostic factors for OS.
Results: OS was not different between the patients treated with antiviral treatment (n = 67) and the patients who received no antiviral treatment (n = 46) (P=0.103). Barcelona Clinic Liver Cancer (BCLC) was independent prognostic factors for OS of HBV-related HCC patients who were treated with TACE. By subgroup analysis, antiviral therapy achieved better survival improvement in BCLC stage B and C (P<0.001) but had no survival improvement in BCLC stage 0 and A (P=0.605). Antiviral therapy was one of the independent prognostic factors for patients with BCLC stage B and C (HR 0.230, 95% CI 0.094-0.565, P=0.001).
Conclusions: Antiviral therapy did not improve survival of HBV-related HCC patients treated with TACE. However, antiviral therapy shows survival benefit only in BCLC stage B and C disease.